0001104659-24-077834.txt : 20240703
0001104659-24-077834.hdr.sgml : 20240703
20240703171655
ACCESSION NUMBER: 0001104659-24-077834
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231117
FILED AS OF DATE: 20240703
DATE AS OF CHANGE: 20240703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Maccecchini Maria-Luisa
CENTRAL INDEX KEY: 0001315018
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39202
FILM NUMBER: 241100933
MAIL ADDRESS:
STREET 1: 1223 FOXGLOVE LANE
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annovis Bio, Inc.
CENTRAL INDEX KEY: 0001477845
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 262540421
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 LINDENWOOD DRIVE, SUITE 225
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 484-875-3192
MAIL ADDRESS:
STREET 1: 101 LINDENWOOD DRIVE, SUITE 225
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: QR Pharma, Inc.
DATE OF NAME CHANGE: 20091202
4
1
tm2417696-3_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-11-17
0
0001477845
Annovis Bio, Inc.
ANVS
0001315018
Maccecchini Maria-Luisa
C/O ANNOVIS BIO, INC.
101 LINDENWOOD DR, SUITE 225
MALVERN
PA
19355
1
1
1
0
President and CEO
0
Common Stock
2024-03-28
4
G
0
10000
0
D
1088459
D
Common Stock
2024-03-31
4
G
0
10000
0
D
1078459
D
Common Stock
2024-03-31
4
G
0
10000
0
D
1068459
D
Stock Option (right to buy)
6.07
2023-11-17
4
A
0
252000
0
A
2033-11-17
Common Stock
252000
252000
D
Stock Option (right to buy)
6.07
2023-11-17
4
A
0
108800
0
A
2033-11-17
Common Stock
108800
108800
D
Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person.
On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.
Stock option will vest in eight consecutive quarterly installments of 31,500 shares each on the 17th day of February, May, August and November of each year, continuing through November 17, 2025.
The stock option was granted in lieu of cash payment for 2023 fiscal year bonus. 100% of the stock option grant listed was also contingent upon the aforementioned amendment to the 2019 Equity Incentive Plan to increase the number of issuable shares from 2,000,000 to 3,000,000. It would have been forfeited if the amendment had not been approved.
The stock option shall vest immediately.
/s/ Maria Maccecchini
2024-07-03